Related Experiment Video
Updated: Jul 24, 2026
10:13
A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
H J Andreyev1, A R Norman, D Cunningham
1Department of Medicine & Therapeutics, Imperial College School of Medicine, Chelsea & Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
British Journal of Cancer
|September 5, 2001
Summary
A specific Kirsten ras (Ki-ras) gene mutation, glycine to valine at codon 12, significantly impacts colorectal cancer survival. This mutation may also drive more aggressive tumor behavior in advanced stages.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Colorectal cancer (CRC) prognosis is influenced by tumor genotype.
- Kirsten ras (Ki-ras) mutations are common in CRC, but their prognostic significance varies.
- Previous analyses of the RASCAL database suggested differential impacts of Ki-ras mutations on patient outcomes.
Purpose of the Study:
- To investigate the prognostic impact of specific Ki-ras mutations in a large cohort of colorectal cancer patients.
- To explore whether the effect of Ki-ras mutations differs across various stages of colorectal cancer.
- To determine if certain Ki-ras mutations are associated with more aggressive tumor biology.
Main Methods:
- A collaborative database (RASCAL) was established, collecting Ki-ras genotype and outcome data from CRC patients worldwide.
- Data from 3439 patients, after exclusion criteria, underwent multivariate analysis.
- Specific mutations at codons 12 and 13 of Ki-ras were analyzed for their association with failure-free and overall survival.
Main Results:
- Among 12 possible mutations at codons 12 and 13, only the glycine to valine mutation at codon 12 (8.6% of patients) showed a statistically significant impact on survival (P=0.004 for failure-free, P=0.008 for overall survival).
- This specific mutation had a more pronounced effect on survival in Dukes' C stage cancers compared to Dukes' B stage cancers.
- The glycine to valine mutation at codon 12 was associated with increased risk of cancer progression and potentially more aggressive biological behavior in advanced colorectal cancer.
Conclusions:
- The glycine to valine mutation at codon 12 of Ki-ras is a significant prognostic marker in colorectal cancer.
- This mutation may play a role in early tumor development and is linked to poorer outcomes in advanced disease.
- Targeting or monitoring this specific Ki-ras mutation could inform treatment strategies for colorectal cancer patients.
Related Concept Videos
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:24Small GTPases - Ras and Rho
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
01:03Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
02:38The Ras Gene
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Ras is a superfamily...